Parkinsonism Induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the Marmoset: Effects of Bromocriptine and L-Dopa

  • S. P. Close
  • A. S. Marriott
  • S. Pay
Part of the Satellite Symposia of the IUPHAR 9th International Congress of Pharmacology book series (SSNIC)

Abstract

Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) appears to have a specific neurotoxic effect upon nigro-striatal neurones in human and Rhesus monkey (Burns et al., 1983; Langston et al., 1983). This lesion gives rise to a parkinsonian syndrome that can be reversed by L-DOPA. We report that MPTP produces a similar but temporary syndrome in the marmoset that can be relieved by bromocriptine and L-DOPA.

Keywords

MPTP Dopa Bromocriptine Mesylate Meperidine 

References

  1. Burns, R.S., Chiueh, C.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M. and Kopin, I.J. (1983). A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A., 80, 4546–4550. PubMedPubMedCentralCrossRefGoogle Scholar
  2. Langston, J.W., Ballard, P., Tetrud, J.W. and Irwin, I. (1983). Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis. Science, 219, 979–980.PubMedCrossRefGoogle Scholar

Copyright information

© The Contributors 1986

Authors and Affiliations

  • S. P. Close
    • 1
  • A. S. Marriott
    • 1
  • S. Pay
    • 1
  1. 1.Department of NeuropharmacologyGlaxo Group Research LtdWareUK

Personalised recommendations